Lianhua Pharmaceutical: Lactulose oral solution approved, with sales expected to reach 563 million yuan in 2025.

Lianhuan Pharmaceutical announced that it has recently received the "Drug Registration Certificate" for lactulose oral solution issued by the National Medical Products Administration. The registration classification is Category 4 chemical drugs, which is regarded as passing the consistency evaluation of quality and efficacy for generics. This drug is indicated for chronic or habitual constipation, helping to regulate the physiological rhythm of the colon; hepatic encephalopathy, used for the treatment and prevention of hepatic coma or pre-coma states. The sales revenue of this drug in hospitals at or above the secondary level nationwide is expected to reach 563 million yuan by 2025. The company has invested approximately 5.297 million yuan in the research and development of this drug. As of the date of this announcement, the company and its subsidiaries have obtained 12 production approvals in total for the year 2026.